1-4 of 4
Eduardo O. Bullorsky
Close
Sort by
Journal Articles

Bosutinib As Therapy for Chronic Phase Chronic Myeloid Leukemia Following Failure with Imatinib Plus Dasatinib and/or Nilotinib: 24-Month Minimum Follow-up Update

H. Jean Khoury, MD, Carlo Gambacorti-Passerini, Hagop M. Kantarjian, MD, Dong-Wook Kim, David Marin, Pedro E Dorlhiac-Llacer, Andrey Zaritskey, Juan Navarro, Eduardo O Bullorsky, Sarit Assouline, Eric Leip, Virginia Kelly, Kathleen Turnbull, Nadine Besson, Jorge E Cortes, MD
Journal: Blood
Blood (2012) 120 (21): 3785.
https://doi.org/10.1182/blood.V120.21.3785.3785
Published: 2012
Journal Articles

Adherence to Imatinib Mesylate Treatment: Two Years Follow up

Carlos A. Doti, M.D., German R Stemmelin, M.D., Elena Beatriz Moiraghi, MD, María Gabriela Flores, MD, Juan Garcia, MD, Hector Murro, MD, Eduardo O Bullorsky
Journal: Blood
Blood (2008) 112 (11): 4267.
https://doi.org/10.1182/blood.V112.11.4267.4267
Published: 2008
Journal Articles

Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase

Clinical Trials & Observations
Francois Guilhot, Jane Apperley, Dong-Wook Kim, Eduardo O. Bullorsky, Michele Baccarani, Gail J. Roboz, Sergio Amadori, Carmino A. de Souza, Jeffrey H. Lipton, Andreas Hochhaus, Dominik Heim, Richard A. Larson, Susan Branford, Martin C. Muller, Prasheen Agarwal, Ashwin Gollerkeri, Moshe Talpaz
Journal: Blood
Blood (2007) 109 (10): 4143–4150.
https://doi.org/10.1182/blood-2006-09-046839
Published: 2007
Journal Articles

Smoking as a Cause for Mild Chronic Neutrophilia.

German R. Stemmelin, MD, Carlos A. Doti, MD, Claudia M. Shanley, MD, Jose M. Ceresetto, MD, Oscar M. Rabinovich, MD, Maria A. Vicente Reparaz, MD, Matias Gonzalez Vukovic, MD, Eduardo O. Bullorsky, MD.
Journal: Blood
Blood (2004) 104 (11): 3796.
https://doi.org/10.1182/blood.V104.11.3796.3796
Published: 2004